Inactief instrument

Andere talen AEON Biopharma, Inc. Nasdaq

Aandelen

Geschatte realtime Cboe BZX Andere beurzen 14:11:23 17-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,81 ^USD	0,00%		0,00%	0,00%

16/07	Top premarket stijgers	MT
09/07	AEON Biopharma, Inc. kondigt een strategische herprioritering aan om een biosimilar pad voor ABP-450 na te streven	CI

Top Premarket Gainers	16/07
AEON Biopharma Plans to Pursue Biosimilar Regulatory Pathway for ABP-450	09/07
AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450	09/07
AEON Biopharma, Inc.(NYSEAM:AEON) added to Russell Microcap Growth Index	01/07
AEON Biopharma, Inc.(NYSEAM:AEON) added to Russell 3000E Index	01/07
AEON Biopharma, Inc.(NYSEAM:AEON) added to Russell Microcap Index	01/07
AEON Biopharma, Inc.(NYSEAM:AEON) added to Russell 3000E Growth Index	01/07
AEON Biopharma, Inc.(NYSEAM:AEON) added to Russell Microcap Value Index	01/07
AEON Biopharma, Inc.(NYSEAM:AEON) added to Russell 3000E Value Index	01/07
AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024	16/05
AEON Biopharma, Inc. Announces Executive Changes	16/05
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine	16/05
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
AEON Biopharma, Inc. Provides Update on Development Pipeline	09/05
US Equity Markets Close Higher Friday Following Weak Jobs Report	03/05
Sector Update: Health Care Stocks Mixed Late Afternoon	03/05
Sector Update: Health Care	03/05
Top Midday Decliners	03/05
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	03/05
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial	03/05

Geen resultaten voor deze zoekopdracht